Eyepoint Historical Cash Flow
| EYPT Stock | USD 7.17 0.48 6.27% |
Analysis of Eyepoint Pharmaceuticals cash flow over time is an excellent tool to project Eyepoint Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 115.5 M or Other Cashflows From Financing Activities of 1.5 M as it is a great indicator of Eyepoint Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Eyepoint Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eyepoint Pharmaceuticals is a good buy for the upcoming year.
Eyepoint |
About Eyepoint Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Eyepoint balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Eyepoint's non-liquid assets can be easily converted into cash.
Eyepoint Pharmaceuticals Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Eyepoint Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Eyepoint Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Eyepoint Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Eyepoint Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyepoint Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.At this time, Eyepoint Pharmaceuticals' Change To Liabilities is comparatively stable compared to the past year. Stock Based Compensation is likely to gain to about 14.6 M in 2025, whereas Depreciation is likely to drop slightly above 396.7 K in 2025.
Eyepoint Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Eyepoint Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eyepoint Pharmaceuticals cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 22.7M | 133.7M | (83.0M) | 185.6M | 213.5M | 224.1M | |
| Free Cash Flow | (14.8M) | (50.3M) | (67.2M) | (1.6M) | (1.4M) | (1.5M) | |
| Change In Working Capital | 20.1M | (1.7M) | (3.0M) | 58.9M | 67.7M | 71.1M | |
| Begin Period Cash Flow | 22.4M | 45.1M | 178.7M | 95.6M | 110.0M | 115.5M | |
| Other Cashflows From Financing Activities | (624K) | 223K | (2.5M) | 1.4M | 1.6M | 1.5M | |
| Depreciation | 2.6M | 2.8M | 2.4M | 464K | 417.6K | 396.7K | |
| Other Non Cash Items | 1.7M | 628K | 23.6M | 1.2M | 1.1M | 1.0M | |
| Capital Expenditures | 362K | 156K | 2.2M | 3.5M | 4.0M | 4.2M | |
| Total Cash From Operating Activities | (14.4M) | (50.1M) | (65.0M) | 1.9M | 1.7M | 1.8M | |
| Change To Account Receivables | 4.8M | (10.6M) | (2.7M) | 14.4M | 13.0M | 13.6M | |
| Net Income | (45.4M) | (58.4M) | (102.3M) | (70.8M) | (63.7M) | (60.5M) | |
| Total Cash From Financing Activities | 37.5M | 216.9M | (690K) | 187.1M | 215.1M | 225.9M | |
| End Period Cash Flow | 45.1M | 178.7M | 95.8M | 281.3M | 323.5M | 339.6M | |
| Change To Liabilities | 4.6M | 1.9M | 7.5M | 1.2M | 1.4M | 1.5M | |
| Stock Based Compensation | 5.5M | 7.4M | 14.2M | 12.1M | 13.9M | 14.6M | |
| Total Cashflows From Investing Activities | (213K) | (362K) | (33.1M) | (17.3M) | (15.5M) | (14.8M) | |
| Change To Inventory | (3.2M) | 1.3M | (760K) | (1.6M) | (1.4M) | (1.3M) | |
| Sale Purchase Of Stock | (90K) | (150K) | (295K) | (169K) | (152.1K) | (144.5K) | |
| Change To Netincome | 9.4M | 7.4M | 6.7M | 38.4M | 44.1M | 46.3M | |
| Change To Operating Activities | 46K | 72K | (28K) | 69K | 62.1K | 59.0K | |
| Net Borrowings | 25.9M | (14.6M) | (146K) | (653K) | (587.7K) | (558.3K) | |
| Issuance Of Capital Stock | 49.9M | 216.8M | 108.5M | 226.2M | 260.1M | 137.3M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.